Merck & Co’s Keytruda reigns supreme among immunotherapies for non-small cell lung cancer (NSCLC), and new data looks set to consolidate that position even further with new data in KRAS-positive ...

A breakthrough in lung ... of lung cancer. The study, featured on the cover of the Journal of Thoracic Oncology, reveals a potential game-changer for patients battling tumors with the KRAS G12C ...

KRAS G12C is the most common form of KRAS mutation in lung cancer, while G12D is found more commonly in other diseases like pancreatic and colorectal cancers. Dr Hu Tao, co-founder and chief ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept pancreatic ... developed immunocompetent model considered the gold ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...

In 2021, the first KRAS inhibitor was approved to treat non-small cell lung cancer with KRAS G12C mutations ... used a Penn-developed immunocompetent model considered the gold standard worldwide ...

These include NSCLC tumors that carry mutations in both the KRAS and LKB1 genes. Patients with this type of cancer ...